Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk

Stuckey, Bronwyn GA; Khatri, Nely Shrestha

doi:10.5694/mja2.51679

Topics

Musculoskeletal diseases

Pharmaceutical preparations

Health occupations

Surgical procedures, operative

In reply: We agree with Goss1 that there should be a conversation between primary physicians and dentists for the best management of patients with osteoporosis. We also agree that osteonecrosis of the jaw is a debilitating disease, as, indeed, are osteoporotic fractures.

1 Keogh Institute for Medical Research, Perth, WA
2 Sir Charles Gairdner Hospital, Perth, WA
3 University of Western Australia, Perth, WA

Correspondence: bronwyn.stuckey@uwa.edu.au

Competing interests:

No relevant disclosures.

1. Goss A. Vertebral fractures after denosumab discontinuation for dental procedures: a consequence of distorted perceptions of risk [letter]. Med J Aust 2022; 217: 268.
2. Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication‐related osteonecrosis of the jaws — 2022 update. J Oral Maxillofac Surg 2022; 80: 920‐943.
3. Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo‐controlled FREEDOM trial and its extension. J Bone Miner Res 2018; 33: 190‐198.
4. Lamy O, Stoll D, Aubry‐Rozier B, Gonzalez Rodriguez E. Stopping denosumab. Curr Osteoporos Rep 2019; 17: 8‐15.
5. Goss A. Evidence‐based guidelines for patients on antiresorptive medications for osteoporosis requiring dental extractions. Australian Dental Association News Bulletin 2021; 515: 22‐24.
6. Therapeutic Guidelines. Medication‐related osteonecrosis of the jaw: dental considerations. https://www.tg.org.au/ viewed May 2022).

Online responses are no longer available. Please refer to our instructions for authors page for more information.